Antibody response to cancer/testis (CT) antigens: A prognostic marker in cancer patients.
Immune responses to tumor antigens have been reported in cancer patients. However, the relevance of such spontaneous immune responses to the clinical course has not been studied extensively. We showed that the overall survival of patients with antibodies against NY-ESO-1 or XAGE1 (GAGED2a) antigen was prolonged in gastric or lung cancer patients, respectively.
Department of Respiratory Medicine; Kawasaki Medical School ; Kurashiki, Japan.
Yoshihiro
Y
Ohue
Department of Clinical Research in Tumor Immunology; Graduate School of Medicine; Osaka University ; Suita, Japan.
Hisashi
H
Wada
Department of Respiratory Medicine; Kawasaki Medical School ; Kurashiki, Japan.
Mikio
M
Oka
Faculty of Health and Welfare; Kawasaki University of Medical Welfare ; Kurashiki, Japan.
Eiichi
E
Nakayama
NY-ESO-1; XAGE1 (GAGED2a); cancer/testis (CT) antigen; overall survival; spontaneous antibody response